On July 21, 2017, the FDA approved OxyCODONE HYDROCHLORIDE tablets under ANDA No. 208593, granting manufacturer KVK-Tech, Inc. immediate access to the U.S. opioid market which is expected to drive the company's revenue growth through the supply of this generic alternative. This certification significantly strengthens KVK-Tech’s portfolio in the analgesic space and intensifies competitive pricing pressures on the brand leader.